Legend Capital

Legend Capital, a subsidiary of Legend Holdings Ltd., was founded in April 2001 and is based in Beijing, China. The firm manages private equity investments across four funds, totaling up to US$700 million, focusing primarily on early-stage ventures and mid-market growth companies. Its investment strategy targets sectors including information technology, telecommunications, media, healthcare, consumer goods, clean technology, and advanced manufacturing, with a strong emphasis on businesses that are either based in China or related to Chinese markets. Legend Capital is known for its active involvement with portfolio companies, providing them with essential business resources and tailored services to enhance development and optimize company performance in the Chinese market. The firm has built a diverse portfolio of over 60 companies, contributing to its reputation as a respected player in China's venture capital industry.

Hao Chen

Vice Chairman

Maggie Fu

Managing Director

Arthur Ge

Managing Director

Frank Hong

Managing Director

Xiaohong Huang

Managing Director

Richard Li

President

Jiaqing Li

President and Managing Director

Joon Park

Managing Director

FAN Qihui

Managing Director

Hong Shangguan

Executive Director

Jenking Shao

Managing Director and Partner

Jeff Wang

Managing Director

Nengguang Wang

Managing Director and CFO

Piau-Voon Wang

Managing Director

Tony Wang

Managing Director and Vice President

Ge Xinyu

Managing Director

Joe Zhou

Managing Director

Hank Zhou

Managing Director and Co-Chief Investment Officer

Linan Zhu

Chairman

392 past transactions

Bio-Engine

Series C in 2023
Bio-Engine specializes in the research and development of veterinary biological products, focusing on the creation and manufacturing of antibodies, recombinant proteins, and vaccines for both human and livestock viruses. The company utilizes high-density serum-free suspension culture technology for animal cells, which enhances the efficiency of its products. Key offerings include serum-free media for various cell types, such as HEK293 and PK15, applicable in fields like cell therapy and vaccine production. In addition to product development, Bio-Engine provides clinical trial services to pharmaceutical manufacturers and scientific research organizations. Founded in 2014 and headquartered in Shanghai, China, the company is committed to advancing biotechnological solutions in the veterinary sector.

Tripod Preclinical Research

Funding Round in 2023
Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.

ZStack

Series C in 2023
ZStack Cloud Platform has served more than 1,000 enterprise users and established ecological and channel partnerships with more than 200 cloud vendors, covering government, finance, education, internet, energy, manufacturing and many other industries.

MacroLux

Series A in 2023
MacroLux operates as a medical technology company focusing on endoscopic interventional business. MacroLux develops endoscopic interventional therapy solutions and promote them to the majority of medical customers.

RUICYCLE

Series B in 2022
RUICYCLE is a high-tech company dedicated to the comprehensive recycling and utilization of lithium batteries. The company specializes in developing solutions for lithium battery recovery, encompassing cascade utilization, material regeneration, and new material recycling. RUICYCLE's innovative technologies offer industry users a closed-loop ecosystem that emphasizes automatic safe crushing and environmentally friendly treatment processes. By focusing on zero pollution and efficient recycling, RUICYCLE aims to address the challenges associated with lithium battery waste and contribute to sustainable practices in the industry.

Tianfu

Series C in 2022
Nanjing Tianfu Software Co., Ltd. is a developer of custom software solutions and intelligent industrial software based in Nanjing, China. Founded in 2011, the company serves various industries, including turbomachinery, hydraulic construction, automotive, aerospace, and shipbuilding. Its offerings encompass a range of technical services, such as CAE pre- and post-processing development, special solver development, industrial design platform construction, and artificial intelligence platform development. Tianfu focuses on meeting the specific needs of its clients by providing tailored software solutions that enhance efficiency and innovation across different sectors.

AKA Robotics

Series A in 2022
AKA Robotics is a developer and manufacturer of specialized robots and intelligent equipment aimed at enhancing efficiency in various industrial applications. The company focuses on providing solutions for rust removal, cleaning, deicing, testing, spraying, and grinding, primarily serving sectors such as shipbuilding, petrochemicals, wind power, offshore platforms, and steel structure bridges. By introducing advanced robotic technologies, AKA Robotics seeks to alleviate workers from hazardous environments characterized by high risk and pollution. This commitment not only supports enterprises in their transformation and modernization efforts but also aligns with broader goals of sustainable development.

Digital Enhancement

Seed Round in 2022
Digital Enhancement, established in 2019, specializes in enhancing radio frequency (RF) performance through advanced digital technologies. The company provides cutting-edge digital front end (DFE) solutions aimed at improving radio linearization for applications such as 5G base stations, WiFi, and mobile devices. Its innovative approach utilizes a proprietary Crest Factor Reduction (CFR) and digital predistortion (DPD) algorithm, which significantly boosts crucial RF metrics, including bandwidth, linearity, efficiency, and power amplifier output, while maintaining cost-effectiveness. By addressing the growing demands for high-frequency, high-bandwidth, compact, and low-power solutions, Digital Enhancement supports clients in accelerating the development of next-generation products in the rapidly evolving telecommunications landscape.

Huili Bio

Series A in 2022
Huili Bio is a synthetic biology company that specializes in enzyme computational design and modification. The firm develops enzymes aimed at enhancing the production of chemical biosynthetic products, specifically for applications in medicine and food supplements. By leveraging advanced computing and engineering techniques, Huili Bio seeks to improve the functionality of enzymes, thus optimizing production processes through innovative chemical methods.

ClinChoice昆翎

Series E in 2022
ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.

TBSTest

Venture Round in 2022
TBSTest Technology is a developer and manufacturer of integrated circuit automatic test equipment, specializing in solutions for semiconductor manufacturers. Founded in 2017 and headquartered in Beijing, China, with additional offices in Xi’an City, Shanghai, and Suwon, South Korea, the company offers a range of products including test boards, software solutions, and memory systems. TBSTest Technology also provides pre-sales and after-sales support for its equipment, accessories, and software systems, catering to clients in integrated circuit design and production, as well as scientific research institutions and educational organizations. The company is dedicated to advancing testing technology for ultra-large-scale integrated circuits, ensuring high-quality performance for enterprise users in the semiconductor industry.

Lipinyun

Series B in 2022
Lipinyun is a tencent strategic investment company. They offer a full-process intelligent sales model, from customer acquisition and screening to customer management and digital asset accumulation, for enterprises diverse sales ecology. Their integration solution helps enterprises realize the upgrade and iteration of digital business.

Nest

Series A in 2022
Nest is a manufacturer of laboratory equipment and consumables primarily focused on the life sciences sector. The company utilizes modern production tools in a large manufacturing facility to create various products, including cytology, microbial detection, and molecular biology consumables. In addition to these offerings, Nest also provides in vitro diagnostic and medical device-related products. By continually researching and developing new fundamental supplies, Nest aims to provide affordable solutions for its customers, ensuring that laboratories have access to essential consumables for their research needs.

Tailan New Energy

Series A in 2022
Tailan New Energy is a company dedicated to the research and development of innovative energy technologies, specifically new solid-state lithium batteries and essential lithium battery materials. Co-founded by experts in lithium battery research and a seasoned industrialization team, it aims to advance the technology and commercialization of these batteries. The company also focuses on electronic special materials and resource recycling, offering a range of services that includes battery sales, battery leasing, and the sale of graphite and carbon products. Through its efforts, Tailan New Energy seeks to contribute to the evolving landscape of energy storage solutions.

Senscomm

Series A in 2022
Senscomm Semiconductor Co., Ltd. is a fabless semiconductor company founded in 2018 and based in Suzhou, China. The company specializes in the research and development of semiconductors and integrated circuits, catering to various sectors, including augmented reality (AR), virtual reality (VR), the Internet of Things (IoT), and electric vehicles (EV). Senscomm has successfully launched over 20 products to meet global demand, demonstrating its commitment to innovation and technological advancement. In addition to its core semiconductor offerings, the company provides machinery equipment and technical consulting services, positioning itself as a comprehensive solution provider in the semiconductor industry.

Fit2Cloud

Series D in 2022
Hangzhou Fit2Cloud Information Technology Co., Ltd., founded in 2014 and based in Beijing, China, operates a comprehensive cloud management platform designed to enhance the management of multi-cloud environments for enterprise customers. The platform includes features such as hybrid IT integration, a control center, self-service operations, resource and cost analysis, DevOps tools, and security audits. FIT2CLOUD serves various industries, including finance, manufacturing, media, energy, telecommunications, and the Internet. By addressing challenges related to IT operation security and continuous application delivery, FIT2CLOUD aims to facilitate smoother management and utilization of cloud services, ultimately supporting enterprises in their digital transformation journey.

ZHIYI TECH

Venture Round in 2022
Developer of an artificial intelligence technology designed to serve in clothing design. The company's AI platform provides integrated solutions to customize personal selection and fashion styles and helps designers capture and determine the popular clothing styles, enabling users to efficiently track the market trend of clothing styles and make better customized clothing products.

Reliable Med

Series A in 2022
Reliable Med is a developer and provider of clinical mass spectrometry equipment designed for in vitro diagnostic (IVD) tests. The company focuses on addressing the needs of the medical industry by offering high-end clinical mass spectrometry devices and IVD detection kits. By doing so, Reliable Med aims to enhance the efficiency and accuracy of patient diagnoses within the healthcare sector.

Qingwei Intelligent Technology

Series B in 2022
Qingwei Intelligent Technology is a Chinese artificial intelligence (AI) chip maker

Medilink Therapeutics

Series B in 2022
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

TuringQ

Seed Round in 2022
TuringQ, established in February 2021, specializes in the research and development of quantum information technology, particularly focusing on optical quantum chips and quantum computing. The company employs lithium niobate on insulator (LNOI) photonic chips and femtosecond laser direct writing techniques to create advanced photonic circuits. TuringQ has made significant advancements in areas such as photonic quantum chips, scientific research-grade photonic quantum computers, and photonic quantum measurement and control systems. Additionally, the company is developing photonic quantum EDA software and cloud platforms aimed at enhancing capabilities in quantum computing. TuringQ's innovations target applications in intelligent computing and power engines, positioning it as a leader in the emerging field of quantum technologies.

GluBio Therapeutics

Series A in 2022
GluBio Pharmaceutical focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

Inceptio Technology

Series B in 2022
Inceptio Technology (Shanghai) Co., Ltd. is an autonomous trucking start-up based in Jiangxi, China, founded in 2018. The company specializes in transforming line-haul logistics through a nationwide freight network that employs autonomous heavy-duty trucks. By leveraging artificial intelligence, new energy technology, and logistics big data, Inceptio Technology aims to enhance the security, efficiency, and cost-effectiveness of transportation services for logistics customers. Its focus on providing transportation-as-a-service positions it to meet the evolving needs of the logistics industry while promoting safer and more efficient freight solutions.

Hoteam Software

Series C in 2022
Shandong Hoteam Software Co., Ltd, established in 1993 and based in Jinan, China, specializes in developing software products for the manufacturing sector. As a subsidiary of China Aerospace Science and Technology Corporation, the company focuses on providing industrial enterprises with comprehensive 3D-centric intelligent manufacturing solutions. Its software platforms encompass three-dimensional design, intelligent management, and visualization technologies, which aim to enhance work efficiency and reduce operational costs for clients engaged in collaborative research and development.

Singlomics

Series B in 2022
Singlomics is a biotechnology company that specializes in single-cell sequencing technology to facilitate antibody drug development aimed at treating infectious diseases and cancers. The company has made significant advancements in antibody discovery, having developed neutralizing antibodies such as DXP593 and DXP604, which offer potential solutions in the fight against COVID-19. By leveraging its innovative technology, Singlomics focuses on creating targeted therapies that address critical health challenges.

ZShield

Series C in 2022
ZShield Inc. provides cyberspace data security and big data business risk management. The company offers production innovation and data security services, information security platform, and AndunTM ZS-ISP which helps government and enterprises. The company was founded in 2014 and is based in Beijing, China.

Beijing Tianxing

Series B in 2022
Beijing Tianxing is a clinical solutions company for sports medicine for implants, arthroscopy devices, and sports medicine equipment.

Leapstack

Series C in 2021
Leapstack is an insurance technology company specializing in big data artificial intelligence technology. It is committed to building big data artificial intelligence solutions for commercial insurance companies and social security management agencies. The company was founded in February 2016 and has received angels from Gaochun Capital and Fumu Assets. It is headquartered in Shanghai and has offices in Beijing and Nanjing.

Xbiome

Series B in 2021
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.

ColorTech Bio

Series B in 2021
ColorTech Bio researches and develops precision molecular diagnostic equipment. It offers medical devices to improve biotechnology services and solutions. ColorTech Bio was founded in 2018 and is based in Suzhou, China.

River Security

Series C in 2021
Silicon Security, founded in 2012, focuses on providing the industry's cutting edge Internet dynamic application security solution. Headquartered in Shanghai, Beijing and Shenzhen, respectively, with branches, and set up a research and development center in Chengdu. Ruimin information after more than two years of research and development, developed a global leader in the leading active defense security technology. The technology completely subvert the traditional continuation of more than 20 years of security technology base, can defend against a variety of unknown modern means of attack, blocking more efficient, more timely, while significantly reducing deployment and use costs.

Jifan Biotechnology

Series B in 2021
Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.

sailner

Seed Round in 2021
Sailner 3D Technology specializes in the development and sale of industrial-grade 3D printers, focusing on color and multi-material printing capabilities. The company's innovative WJP white ink filling technology enables voxel-level precision, allowing for the creation of detailed and customizable products. Sailner's 3D printing solutions find applications in various sectors, including digital medical education, surgical planning, and industrial design, as well as in the production of high-precision jewelry models. Through its commitment to research and development, Sailner aims to enhance additive manufacturing technology and provide tailored applications to meet diverse industrial needs.

TuringQ

Seed Round in 2021
TuringQ, established in February 2021, specializes in the research and development of quantum information technology, particularly focusing on optical quantum chips and quantum computing. The company employs lithium niobate on insulator (LNOI) photonic chips and femtosecond laser direct writing techniques to create advanced photonic circuits. TuringQ has made significant advancements in areas such as photonic quantum chips, scientific research-grade photonic quantum computers, and photonic quantum measurement and control systems. Additionally, the company is developing photonic quantum EDA software and cloud platforms aimed at enhancing capabilities in quantum computing. TuringQ's innovations target applications in intelligent computing and power engines, positioning it as a leader in the emerging field of quantum technologies.

Qutronix

Seed Round in 2021
Qutronix is a company focused on the development of optical quantum chips and quantum computing technologies. It aims to advance the industrialization of quantum information and intelligent technology by utilizing photonic chips. The company offers quantum secure communication services and comprehensive solutions for remote confidential control in the Internet of Things sector. Its cutting-edge three-dimensional integrated optical quantum chip, created through femtosecond laser direct writing technology, serves as a promising resource for quantum computing and processing. Additionally, Qutronix provides a platform for research into analog quantum computers, assisting clients in exploring advanced applications such as power factor optimization and quantum search algorithms, thereby fostering connections between theoretical algorithms and practical engineering solutions.

Biortus Biosciences

Series B in 2021
Wuxi Biortus Biosciences Co. Ltd. is a contract research organization based in Jiangyin, China, specializing in research and development services that support drug discovery. Founded in 2009, the company offers a range of services including recombinant protein production, in vitro assays and screening, medicinal chemistry, structural biology, and target validation. These services are designed to assist pharmaceuticals, biotechnology firms, and research institutions in achieving their drug discovery objectives. Biortus has established five advanced research platforms and has developed innovative techniques, some of which are patented. The company operates as a subsidiary of Jiangsu Shuangliang Group Company Ltd.

Wangdiantong

Series D in 2021
Wangdiantong ERP is an enterprise-level e-commerce ERP, supporting Taobao, Tmall, Jingdong, Amazon, Dangdang, No. 1 shop, Alibaba and many other platforms, supporting multi-warehouses, support online stores and physical store cashiers. Including goods management, inventory, orders, purchasing, after-sales, accounts, statistics, CRM and other rich features.

ForQaly

Series B in 2021
Developer of minimally invasive ventricular assist devices. The company's products with advantages of small trauma, large auxiliary flow, and easy to use, providing a circulation improvement plan that doctors can use conveniently and patients can afford.

H.Extract

Series C in 2021
H.Extract, established in 2010 and based in Qingdao, China, specializes in producing natural extracts from various spices such as pepper, ginger, garlic, and cumin for the food manufacturing sector. The company focuses on the research and development of high-quality extracts to meet the needs of food producers, enhancing flavor and nutritional value in their products. H.Extract is committed to maintaining industry standards and ensuring customer satisfaction through its innovative solutions and dedication to quality. With a growing reputation in the market, the company continues to expand its product offerings and strengthen its position within the food industry.

HC Scientific

Series B in 2021
HC Scientific Technology Co., Ltd. is a company based in Chengdu, China, that specializes in the development, manufacturing, and distribution of genetic testing instruments, reagents, and software. Founded in 2015, the company serves various sectors, including clinical molecular diagnostics, health genetic testing, and agricultural molecular breeding, both domestically and internationally. HC Scientific's product lineup features instruments such as the Matrix Arrayer for reaction plate preparation, the Matrix Cycler for thermal cycling, and the Matrix Scanner for fluorescence detection. Additionally, the company provides consumables like the Matrix plate and Matrix Mix genotyping reagents, along with a data management system known as Matrix Master. Committed to innovation, HC Scientific focuses on autonomous research and development of its intellectual property, aiming to deliver high-throughput, automated, and cost-effective genetic testing solutions.

LYNK Pharmaceuticals

Series B in 2021
LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Berry Oncology

Series B in 2021
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.

BioMap

Series A in 2021
Developer of biotechnologies designed to drive new drugs research and development. The company allows scientists to model life more accurately from proteins to a system level and extract novel insights and predictions from limited data, supported by an international, cross-functional team, enabling physicians to enhance the effectiveness rate of new drugs.

Mathpresso

Series C in 2021
Mathpresso, Inc. is an educational technology company based in Seoul, South Korea, established in 2015. It operates Qanda, a data-driven platform that leverages artificial intelligence and optical character recognition (OCR) technology to assist students with their studies. Users can take a photo of a question or problem, which the platform then analyzes to provide solutions and explanations. Qanda covers a wide range of subjects, including mathematics, Korean history, social studies, and science. The platform is designed to facilitate learning by allowing students to engage with tutors and access answers in real time. As of this year, Qanda has attracted over one million users in South Korea, making it a significant resource for students seeking help with homework and exam preparation.

Yeasen

Series B in 2021
Developer and producer of enzymes and antibodies designed to serve in life science industry. The company is committed to research and development of enzymes and antibodies and providing high-quality products and services including reverse transcription, molecular cloning, and cell culture, enabling life scientist to facilitate their field research and enhance the advancement of life science.

RecBio

Series C in 2021
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.

Horizon Robotics

Series C in 2021
Horizon Robotics, founded in 2015 and headquartered in Beijing, China, specializes in developing advanced chips for robotics and artificial intelligence applications. The company focuses on providing integrated, open embedded AI solutions that are designed to be high-performance, low-power, and cost-effective. Horizon Robotics aims to enable a wide range of devices, including autonomous vehicles, to operate with enhanced intelligence, facilitating capabilities such as perception, understanding, and decision-making to improve safety and convenience. The company's co-founding team possesses expertise in algorithms, software, hardware, and chip development, supported by a robust research and development team with significant industry experience. Horizon Robotics has garnered considerable investment from prominent venture capital firms and notable investors, positioning itself as a leading player in the global AI startup landscape.

Reliable Med

Series A in 2021
Reliable Med is a developer and provider of clinical mass spectrometry equipment designed for in vitro diagnostic (IVD) tests. The company focuses on addressing the needs of the medical industry by offering high-end clinical mass spectrometry devices and IVD detection kits. By doing so, Reliable Med aims to enhance the efficiency and accuracy of patient diagnoses within the healthcare sector.

Fiture

Series B in 2021
Fiture is a fitness technology company focused on transforming home fitness through innovative hardware and artificial intelligence. The company offers customized online workout courses alongside the manufacturing of intelligent home workout equipment. By leveraging AI technologies, Fiture aims to enhance user experience and support clients in achieving healthier lifestyles through effective at-home fitness solutions.

Stonewise

Series B in 2021
Beijing StoneWise Technology Co., Ltd. is a technology company founded in 2018 that specializes in artificial intelligence-driven solutions for drug discovery. The company's platform integrates advanced technologies, including artificial intelligence, microfluidics, computational chemistry, and pharmacology, to enhance the efficiency and success rates of early-stage drug development. StoneWise focuses on the research and repurposing of nucleoside-based RNA polymerase inhibitors, particularly regarding their potential applications in treating COVID-19. The platform offers a variety of tools, such as medical knowledge graphs and molecular design capabilities, aimed at pharmaceutical enterprises and research institutions. By collaborating with both domestic and international experts in various scientific fields, StoneWise is committed to transforming traditional drug research methodologies and providing comprehensive solutions to improve drug discovery outcomes.

Kunlun

Venture Round in 2021
Kunlun is an artificial intelligence chip designer and manufacturer.

Sciwind Biosciences

Series B in 2021
Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company specializing in the development and sale of protein and peptide drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company focuses on therapeutic areas such as diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neuro-degenerative conditions. Sciwind's innovative drug candidates are particularly targeted at metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for healthcare professionals and their patients.

Liangyihui

Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. develops anti-cancer academic platform for cancer patients. The company is based in Shanghai, China.

Exegenesis Bio

Series B in 2021
Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Jifan Biotechnology

Series A in 2021
Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.

MicuRx Pharmaceuticals

Series E in 2020
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

Wangdiantong

Series C in 2020
Wangdiantong ERP is an enterprise-level e-commerce ERP, supporting Taobao, Tmall, Jingdong, Amazon, Dangdang, No. 1 shop, Alibaba and many other platforms, supporting multi-warehouses, support online stores and physical store cashiers. Including goods management, inventory, orders, purchasing, after-sales, accounts, statistics, CRM and other rich features.

Bruco Group

Series A in 2020
Bruco uses innovative technology to create the ultimate product experience and create long-term value for users. The group currently has four core business segments, including Bruker Building Blocks, Bruker Animation, Bubble Education, and Brock Education. Bruco strives to create a whole ecological industry chain with "building blocks +" as the core, and at the same time applies to build blocks to various application scenarios, and lays out a complete T (Toy toy) + A (Animation animation) + G (Game game) +E (Education Education) industry vision.

Xbiome

Series B in 2020
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.

GalaxySpace

Series C in 2020
GalaxySpace develops and builds LEO broadband satellite constellation, and 5G communication network. The company’s satellite applications include monitoring of airport, parking, and oil reserves, as well as assess land types and uses. GalaxySpace was founded in 2016 and is based in Haidian, China.

LYNK Pharmaceuticals

Series A in 2020
LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Aqrose Technology

Series B in 2020
Beijing Aqrose Technology Co., Ltd. is a high-tech company specializing in the research and development of computer vision and robotic technology for industrial automation. Founded in 2017, the company is based in Beijing, China, and leverages artificial intelligence to enhance manufacturing processes. Aqrose Technology offers a range of products, including an artificial intelligence deep learning visual inspection platform known as AIDI, which addresses industrial challenges such as defect detection and classification. The company also provides intelligent robots, like AIPICK, equipped with 3D vision technology and AI-based defect inspection systems. With a founding team originating from the Artificial Intelligence Laboratory of Tsinghua University, Aqrose Technology is committed to advancing industrial automation through innovative machine vision and machine learning solutions, thereby empowering advanced manufacturing and smart logistics sectors in China.

Genskey

Series C in 2020
Beijing Genskey Technology Co., Ltd. is a medical diagnostic service provider specializing in genetic testing. Founded in 2007 and headquartered in Beijing, China, the company employs high-throughput sequencing technology combined with intelligent algorithm analysis to enhance pathogen diagnosis. Genskey aims to address common challenges in the medical diagnostics field, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of diagnostic results, Genskey seeks to ensure that patients suffering from severe infections receive prompt and accurate diagnoses, ultimately contributing to better health outcomes.

Zhenkunhang

Series E in 2020
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
Hemu (China) Biological Engineering is a Chinese blood vessel intervention medical equipment firm.

Delova Biotech

Venture Round in 2020
Delova Biotech is focused on developing non-opioid analgesics aimed at pain treatment. The company leverages its extensive research and development experience, along with advanced preparation technology platforms, to enhance existing medications and create improved new analgesics in both China and the United States. Delova Biotech employs innovative technologies, including long-acting injection methods, transdermal formulations, nano-delivery systems, prodrug modifications, and techniques to improve the solubility of insoluble drugs. Through these efforts, the company strives to provide patients with higher quality medications that can significantly enhance their quality of life.

LEADRIVE

Series B in 2020
Leadrive Technology (Shanghai) Co.,Ltd. manufactures homebred power modules and electric vehicle solutions. The company offers products, such as Power Module, Power Control Unit, and Motor. Leadrive Technology (Shanghai) Co.,Ltd. was founded in 2017 and is based in Shanghai, China with additional offices in Shanghai, China; and Aachen, Germany.

Haihe Biopharma

Series B in 2020
HaiHe Biopharma is a developer of innovative anti tumor drugs designed to overcome complex diseases and improve pharmacological evaluation. The company focuses on discovery, development and commercialization of innovative anti-tumor drugs, pharmacological efficacy evaluation and provide products including novel topoisomerase I inhibitors and oral c-Met highly selective inhibitors, enabling customers to improve their health conditions and research quality in an efficient manner.

Tongcheng Shenghuo

Series C in 2020
Tongcheng Life is a community O2O group purchase service platform. With the community as a unit, it establishes a community sales office and completes offline delivery. The platform provides supply, logistics, storage and after-sales support. It mainly provides primary edible agricultural products, food, daily necessities, flowers and gardening, and crafts. , Beauty products and other services.

Uditech

Series B in 2020
Shenzhen Uditech Co., Ltd. is a technology-driven company focused on the development and manufacture of robots for various service sectors, including restaurants, hospitals, and entertainment. Established in 2013 and headquartered in Shenzhen, China, Uditech's product offerings include robots equipped with advanced features such as face recognition, obstacle avoidance, multi-machine operation, food ordering and delivery, smart voice communication, and item transportation. In addition to robotics, the company also produces quad-core processors. With a commitment to innovation, Uditech aims to enhance service efficiency through its cutting-edge technology solutions.

iBeiDiao

Series B in 2020
iBeiDiao is a SaaS background check platform that combines with the Internet.

Novast

Venture Round in 2020
Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.

Wangdiantong

Series B in 2020
Wangdiantong ERP is an enterprise-level e-commerce ERP, supporting Taobao, Tmall, Jingdong, Amazon, Dangdang, No. 1 shop, Alibaba and many other platforms, supporting multi-warehouses, support online stores and physical store cashiers. Including goods management, inventory, orders, purchasing, after-sales, accounts, statistics, CRM and other rich features.

Qingju

Venture Round in 2020
Qingju is a bike sharing company.

ANYCOLOR

Post in 2020
Ichikara Inc. is an entertainment start-up based in Tokyo, Japan, founded in 2017. The company specializes in creator support and licensing, primarily focusing on the management and operation of virtual streamers associated with the "Nijisanji Project." Ichikara offers a range of services, including access to distribution studios, advertising partnerships, event coordination, and opportunities for program appearances. Additionally, the company actively seeks to discover new talent through auditions, aiming to enhance the virtual entertainment landscape. By leveraging advanced technology, Ichikara strives to create engaging experiences that resonate with audiences globally.

Harbour BioMed

Series B in 2020
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.

Feiyu

Series A in 2020
Shanghai Feiyu Network Technology Co., Ltd. operates a luxury products trading platform. It sells bags, accessories, watches, footwear, and clothes. The company is based in Shanghai, China.

JenaValve Technology

Series D in 2020
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.

Genskey

Series B in 2020
Beijing Genskey Technology Co., Ltd. is a medical diagnostic service provider specializing in genetic testing. Founded in 2007 and headquartered in Beijing, China, the company employs high-throughput sequencing technology combined with intelligent algorithm analysis to enhance pathogen diagnosis. Genskey aims to address common challenges in the medical diagnostics field, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of diagnostic results, Genskey seeks to ensure that patients suffering from severe infections receive prompt and accurate diagnoses, ultimately contributing to better health outcomes.

Lunit

Series C in 2020
Lunit Inc. is a South Korean company that specializes in developing advanced algorithms for medical image analysis and general object detection using machine learning technology. The firm focuses on areas such as digital chest X-ray, digital mammography, digital pathology, and fundus photography. By leveraging cutting-edge deep learning techniques, Lunit aims to assist physicians in making accurate and efficient clinical decisions. The company has demonstrated its expertise in image recognition, having ranked among the top five in the ImageNet Challenge, a prominent competition in the field. Lunit's technology is notable for its ability to utilize weakly labeled data, enhancing its pattern recognition capabilities. Supported by significant venture capital investments, Lunit is actively engaged in large-scale research collaborations with major university hospitals in South Korea, reflecting its strong reception within the medical community.

Nanovision

Series B in 2019
Nanovision Technology, based in the Zhongguancun Yongfeng high-tech industrial base with an additional subsidiary in Chengdu, specializes in high-speed and high-precision radiology imaging. The company focuses on the development of static CT, X-ray CMOS detectors, and X-ray imaging software. Notably, Nanovision created China's first self-developed CMOS flat panel detector, known as the Merak series. Its products are applicable in various sectors, including medical, industrial, and security, offering advanced technological support both domestically and internationally. With a significant research and development foundation, Nanovision is positioned as a key player in the radiation imaging industry.

Dongfang Weiyin

Series C in 2019
Dongfang Weiyin is a financial service platform focused on small and micro enterprises. Established in 2015 and headquartered in Beijing, China, the company specializes in developing DFWYBANK.com, an accounting and tax database solution tailored for banks, tax bureaus, and small to medium-sized businesses. Through its services, Dongfang Weiyin aims to enhance financial management and compliance for its clients, contributing to the growth and sustainability of smaller enterprises in the Chinese market.

Suzhou Ribo Life Science

Series C in 2019
Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.

RT-Thread

Series B in 2019
RT-Thread is a Shanghai-based company established in 2006 that specializes in developing an open-source real-time operating system (RTOS) for embedded devices. The RTOS is designed for a wide range of applications, particularly in the Internet of Things (IoT) sector, offering features such as cross-chip compatibility, cloud integration, ultra-low power consumption, and security. The system includes a device virtual file system, a device manager framework, low-power management, and firmware update capabilities. RT-Thread supports both resource-constrained microcontroller systems with its Nano version, which requires minimal memory, and more resource-rich IoT devices, allowing for modular customization through user-friendly tools. The company serves various industries, including new energy, home appliances, and transportation, providing a stable and scalable platform that facilitates easy access to major IoT cloud services.

Xbiome

Series B in 2019
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.

Gambol Pet Group

Series B in 2019
Gambol Pet Group Co., Ltd is a pet food manufacturer based in Liaocheng City, China, founded in 2006. The company specializes in a diverse range of products, including dry and wet pet food, real meat jerky treats, rawhide chews, and dental bones, catering to both dogs and cats. Its product lineup features various categories such as pet treats made from chicken, duck, pork, lamb, and fish, as well as wet food incorporating meat, fruits, and vegetables. Gambol Pet Group is committed to research and development, ensuring that its offerings include nutritional supplements and natural ingredients. The company distributes its products across Europe, Asia, and North America, serving a wide customer base. Under the leadership of Chairman and CEO Qin Hua, Gambol Pet Group continues to expand its presence in the pet food industry.

dMed

Series B in 2019
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Mathpresso

Series B in 2019
Mathpresso, Inc. is an educational technology company based in Seoul, South Korea, established in 2015. It operates Qanda, a data-driven platform that leverages artificial intelligence and optical character recognition (OCR) technology to assist students with their studies. Users can take a photo of a question or problem, which the platform then analyzes to provide solutions and explanations. Qanda covers a wide range of subjects, including mathematics, Korean history, social studies, and science. The platform is designed to facilitate learning by allowing students to engage with tutors and access answers in real time. As of this year, Qanda has attracted over one million users in South Korea, making it a significant resource for students seeking help with homework and exam preparation.

Mancando

Series A in 2019
Mancando is an automotive parts supplier company that provides car wearing parts for auto repair factory. They are an innovative model of traditional auto parts management, internet, and platform management. The company was founded in August 2015 and is based in Guangzhou, Guangdong, China.

GalaxySpace

Series B in 2019
GalaxySpace develops and builds LEO broadband satellite constellation, and 5G communication network. The company’s satellite applications include monitoring of airport, parking, and oil reserves, as well as assess land types and uses. GalaxySpace was founded in 2016 and is based in Haidian, China.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.